How Eli Lilly Is Using AI to Reinvent Drug Discovery, Manufacturing and Patient Care скачать в хорошем качестве

How Eli Lilly Is Using AI to Reinvent Drug Discovery, Manufacturing and Patient Care

In this episode of Authentic and Agentic, host Jayson Manship sits down at Eli Lilly’s corporate center with Tim Coleman and Thomas Fuchs to explore how the 150-year-old medicines company is becoming an AI-forward organization. The conversation examines how Lilly aligned leadership around artificial intelligence as a strategic pillar, not just a bolt-on technology. Coleman, Lilly's Chief Technical Officer, outlines three foundational moves that shaped the company’s approach: experimentation, governance and education. From alpha and beta testing AI tools to executive education programs with Purdue University’s Daniels School of Business, Lilly invested early in building structure before scaling. Fuchs, Lilly’s Chief AI officer, explains why failure is central to machine learning and why decades of both successful and failed pharmaceutical experiments give the company a powerful data advantage. The discussion highlights how proprietary data, digital twins in manufacturing, molecular design and internally developed foundation models are reshaping the pharmaceutical value chain. The episode also covers leadership alignment, executive sponsorship, AI governance and regulatory policy. The guests discuss why C-suite commitment is non-negotiable, how guardrails enable speed and why harmonized global standards for AI in health care matter. For executives and business leaders in Indiana and beyond, Coleman and Fuchs share practical advice: start with your strengths, use AI to augment your expertise and focus on delivering real business value rather than chasing shiny tools. Authentic and Agentic is part of the IBJ Media Podcast Network and explores the human side of AI. Learn more at www.jaysonmanship.com